Braveheart Bio, Inc.
BRVENext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for BRVE. That does not mean none is planned.
Get an email about BRVE's next catalysts
Track Braveheart Bio (BRVE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
BRVE Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.91 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BHB-1893 | Phase 3 | Cardiomyopathy, Hypertrophic Obstructive | - | - |
Frequently asked questions
What is in Braveheart Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Braveheart Bio, Inc.'s (BRVE) pipeline across Phase 3. Its lead program is BHB-1893 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Braveheart Bio, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Braveheart Bio, Inc. (BRVE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BRVE biotech catalysts?→
Add BRVE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Braveheart Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.